These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9408605)

  • 1. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
    Xiang J; Qi Y; Chen Y
    Cancer Gene Ther; 1997; 4(6):353-8. PubMed ID: 9408605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
    Wright P; Zheng C; Moyana T; Xiang J
    Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau.
    Qi Y; Moyana T; Chen Y; Xiang J
    Hum Antibodies Hybridomas; 1996; 7(1):21-6. PubMed ID: 8886833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN-gamma [corrected] elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
    Qi Y; Chen Y; Xiang J
    J Interferon Cytokine Res; 1996 Oct; 16(10):771-6. PubMed ID: 8910761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor vaccination with gene-transduced tumor cells expressing a fusion protein RM4/IFN-tau.
    Xiang J
    Cancer Biother Radiopharm; 1997 Apr; 12(2):123-30. PubMed ID: 10851456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1.
    Xiang J; Moyana T
    J Interferon Cytokine Res; 2000 Apr; 20(4):349-54. PubMed ID: 10805368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells.
    Xiang J; Qi Y; Cook D; Moyana T
    Hum Antibodies Hybridomas; 1996; 7(1):2-10. PubMed ID: 8886831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant tumor regression induced by microencapsulation of recombinant tumor cells secreting fusion protein.
    Shi M; Hao S; Quereshi M; Guo X; Zheng C; Xiang J
    Cancer Biother Radiopharm; 2005 Jun; 20(3):260-6. PubMed ID: 15989471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
    Xiang J; Moyana T
    Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
    Liu Y; Xia D; Li F; Zheng C; Xiang J
    Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic engineering of a recombinant fusion possessing anti-tumor F(ab')2 and tumor necrosis factor.
    Xiang J; Moyana T; Qi Y
    J Biotechnol; 1997 Feb; 53(1):3-12. PubMed ID: 9165756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
    Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
    Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule.
    Lu Y; Yamauchi N; Koshita Y; Fujiwara H; Sato Y; Fujii S; Takahashi M; Sato T; Kato J; Yamagishi H; Niitsu Y
    Gene Ther; 2001 Apr; 8(7):499-507. PubMed ID: 11319616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration.
    Sato T; Yamauchi N; Sasaki H; Takahashi M; Okamoto T; Sakamaki S; Watanabe N; Niitsu Y
    Cancer Res; 1998 Apr; 58(8):1677-83. PubMed ID: 9563482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of in vivo tumor growth by the beta chemokine, TCA3.
    Laning J; Kawasaki H; Tanaka E; Luo Y; Dorf ME
    J Immunol; 1994 Nov; 153(10):4625-35. PubMed ID: 7963535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.